Furoxone

(Furazolidone)

ApprovedSmall molecule

UUniversity of New Hampshire

Furoxone is one of 35 small molecule programs targeting Duodenal Ulcer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Duodenal UlcerActive, not recruiting

Helicobacter Pylori EradicationUnknown status

Bismuth Quadruple TherapyRecruiting

Duodenal UlcerApproved

Active, not recruiting

Helicobacter Pylori EradicationApproved

Unknown status

Bismuth Quadruple TherapyApproved

Recruiting

Competition

Competitive Landscape

19 competitors in Helicobacter Pylori Eradication

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

15 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

20 3

Flagyl

DDePuy Orthopaedics

Approved

9 4

Takecab

PPhathom Pharmaceuticals, Inc.

Approved

7 5

Potassium Citrate

MMission Pharmacal

Approved

4 6

Levaquin

WWim Janssens

Approved

3 7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 8

Aciphex

Akero Therapeutics

Approved

2 9

Minocin

TTriax

Approved

1 10

Furoxone

UUniversity of New Hampshire

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Helicobacter Pylori3 trials

Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin

Unknown status·SShandong University·Phase 4·NCT05135182·170 enrolled

Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin

Unknown status·SShandong University·Phase 4·NCT04264663·250 enrolled

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Unknown status·YYanqing Li·Phase 4·NCT03139253·120 enrolled

Helicobacter3 trials

Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT03609892·658 enrolled

Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Completed·YYongquan Shi·Phase 4·NCT06168084·688 enrolled

Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT04678492·658 enrolled

AIN2 trials

A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication

Completed·SShandong University·Phase 4·NCT03716622·350 enrolled

Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy

Unknown status·SSir Run Run Shaw Hospital·Phase 4·NCT02894268·300 enrolled

Helicobacter Pylori Eradication2 trials

Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04907747·234 enrolled

The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

Not yet recruiting·NNanjing First Hospital, Nanjing Medical University·Phase 1·NCT06777732·672 enrolled

Helicobacter Pylori Infection2 trials

Empirical Rescue Therapies of Helicobacter Pylori Infection

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01668927·424 enrolled

Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05718609·855 enrolled

3 more indications

Bismuth Quadruple Therapy1 trial

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment

Recruiting·YYongquan Shi·Phase 4·NCT07139366·1,248 enrolled

Duodenal Ulcer1 trial

The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers

Completed·TThe Third Xiangya Hospital of Central South University·Phase 4·NCT03342456·184 enrolled

H Pylori Infection1 trial

Furazolidone Quadruple Regimen Eradicate H. Pylori Infection

Completed·LLiaocheng People's Hospital·Phase 1/2·NCT06823791·493 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

FUROXONE

NDA NDA011323

Jan 1, 1982

FUROXONE

NDA NDA011270

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Furazolidone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Furazolidone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Furazolidone. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA011323). U.S. Food & Drug Administration.
[5]
SEC EDGAR — University of New Hampshire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of New Hampshire

Furoxone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Helicobacter Pylori3 trials

Helicobacter3 trials

AIN2 trials

Helicobacter Pylori Eradication2 trials

Helicobacter Pylori Infection2 trials

Bismuth Quadruple Therapy1 trial

Duodenal Ulcer1 trial

H Pylori Infection1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News